시장보고서
상품코드
1130704

세계의 조영 증강 초음파 시장 예측(2022-2030년)

Global Contrast Enhanced Ultrasound Market Forecast 2022-2030

발행일: | 리서치사: Inkwood Research | 페이지 정보: 영문 235 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 조영 증강 초음파 시장 규모는 2022-2030년간 연평균 복합 성장률(CAGR) 5.25%의 성장이 예측됩니다. 만성질환 증가, 진단 기술의 발전, 의료 종사자의 조영 증강 초음파 선호가 주요 시장 성장요인이 되고 있습니다.

세계의 조영 증강 초음파(Contrast Enhanced Ultrasound) 시장에 대해 조사분석했으며, 시장 전체, 시장 역학, 시장 예측, 주요 부문별 평가 지역 분석, 주요 애널리틱스, 경쟁 구도 등에 대한 최신 정보를 제공합니다.

목차

제1장 조사 범위와 조사 방법

제2장 개요

제3장 시장 역학

  • 주요 성장요인
    • 만성질환 확대
    • 의료 종사자의 조영 증강 초음파 선호
    • 진단 기술의 발전
  • 주요 성장 억제요인
    • 조영제의 불균일성
    • 현재 의료제도에서의 어려운 채택

제4장 주요 분석

  • 조영 증강 초음파에 대한 COVID-19의 영향
  • 주요 시장 동향
  • Porter의 산업 분석
  • 기회 매트릭스
  • 벤더 구도
  • 밸류체인 분석
  • 주요 구입 기준
  • 규제 프레임워크

제5장 시장 : 제품별

  • 장비
  • 조영제

제6장 시장 : 유형별

  • 비표적형
  • 표적형

제7장 시장 : 최종사용자별

  • 병원
  • 클리닉
  • 외래진료센터

제8장 지역 분석

  • 북미
  • 유럽
  • 아시아태평양
  • 기타 지역

제9장 경쟁 구도

  • 주요 전략적 발전
  • 기업 개요
    • BAYER AG
    • BRACCO DIAGNOSTIC INC
    • DAIICHI SANKYO COMPANY LIMITED
    • GE HEALTHCARE
    • KONINKLIJKE PHILIPS NV
    • LANTHEUS MEDICAL IMAGING INC
    • NANOPET PHARMA GMBH
    • SANOCHEMIA PHARMAZEUTIKA GMBH
    • SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO LTD
    • SIEMENS HEALTHINEERS AG
    • TAEJOON PHARM
    • TRIVITRON HEALTHCARE
LSH 22.10.13

KEY FINDINGS

The global contrast enhanced ultrasound market is expected to register a CAGR of 5.25% during the forecast period, 2022-2030. The increasing prevalence of chronic disease, advanced technologies for diagnosis, and rising preference for contrast enhanced ultrasound imaging among health practitioners are the primary growth drivers.

MARKET INSIGHTS

Contrast enhanced ultrasound is a medical imaging test that uses intravenous agents containing microbubbles. Contrast helps providers view the blood flow through blood vessels and organs. Chronic diseases are on the rise worldwide, pressurizing the health systems working diligently to deliver high-quality chronic care management. Simultaneously, several public health programs are pushing for periodic screening examinations to detect specific chronic diseases. For instance, cardiovascular diseases, diabetes, and cancer. Accordingly, new delivery models and advancements in precise diagnosis and detection of disease are evaluated to reduce the cost of treating chronic conditions.

Furthermore, the extensive use of contrast enhanced ultrasound is a measure that has facilitated a major breakthrough in diagnostic ultrasound. It projects the micro- and macro-circulation of the targeted organ. It is commonly used in oncology to delineate information like blood flow, location, and tumor size. As a result, the surging prevalence of chronic diseases is a major growth driver of the global contrast enhanced ultrasound market. However, the market growth is restrained by difficulty in adopting contrast enhanced ultrasound in the current healthcare system.

REGIONAL INSIGHTS

The geographical analysis of the global contrast enhanced ultrasound market growth includes North America, Europe, Asia-Pacific, and Rest of World. North America is set to garner the largest revenue share in the global market, largely attributed to the growing cases of various health conditions.

COMPETITIVE INSIGHTS

The market is highly fragmented due to the presence of several regional and multinational companies. Some of the leading players in the market include Acusphere Inc, Siemens Healthineers AG, GE Healthcare, Koninklijke Philips NV, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation caters to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. KEY DRIVERS
    • 3.1.1. SURGING PREVALENCE OF CHRONIC DISEASES
    • 3.1.2. HEALTH PRACTITIONERS PREFER CONTRAST ENHANCED ULTRASOUND IMAGING
    • 3.1.3. TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSIS
  • 3.2. KEY RESTRAINTS
    • 3.2.1. NON-UNIFORMITY OF CONTRAST AGENTS
    • 3.2.2. DIFFICULTY IN ADOPTION IN THE CURRENT HEALTHCARE SYSTEM

4. KEY ANALYTICS

  • 4.1. IMPACT OF COVID-19 ON CONTRAST ENHANCED ULTRASOUND MARKET
  • 4.2. KEY MARKET TRENDS
  • 4.3. PORTER'S FIVE FORCES ANALYSIS
    • 4.3.1. BUYERS POWER
    • 4.3.2. SUPPLIERS POWER
    • 4.3.3. SUBSTITUTION
    • 4.3.4. NEW ENTRANTS
    • 4.3.5. INDUSTRY RIVALRY
  • 4.4. OPPORTUNITY MATRIX
  • 4.5. VENDOR LANDSCAPE
  • 4.6. VALUE CHAIN ANALYSIS
  • 4.7. KEY BUYING CRITERIA
    • 4.7.1. COST EFFICIENCY
    • 4.7.2. PRODUCT FEATURES
    • 4.7.3. END-USE
  • 4.8. REGULATORY FRAMEWORK

5. MARKET BY PRODUCT

  • 5.1. EQUIPMENT
  • 5.2. CONTRAST AGENT

6. MARKET BY TYPE

  • 6.1. NON-TARGETED
  • 6.2. TARGETED

7. MARKET BY END-USER

  • 7.1. HOSPITALS
  • 7.2. CLINICS
  • 7.3. AMBULATORY DIAGNOSTIC CENTERS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. MARKET SIZE & ESTIMATES
    • 8.1.2. KEY GROWTH ENABLERS
    • 8.1.3. KEY CHALLENGES
    • 8.1.4. KEY PLAYERS
    • 8.1.5. COUNTRY ANALYSIS
      • 8.1.5.1. UNITED STATES
      • 8.1.5.2. CANADA
  • 8.2. EUROPE
    • 8.2.1. MARKET SIZE & ESTIMATES
    • 8.2.2. KEY GROWTH ENABLERS
    • 8.2.3. KEY CHALLENGES
    • 8.2.4. KEY PLAYERS
    • 8.2.5. COUNTRY ANALYSIS
      • 8.2.5.1. UNITED KINGDOM
      • 8.2.5.2. GERMANY
      • 8.2.5.3. FRANCE
      • 8.2.5.4. ITALY
      • 8.2.5.5. SPAIN
      • 8.2.5.6. NORDIC COUNTRIES
      • 8.2.5.7. REST OF EUROPE
  • 8.3. ASIA-PACIFIC
    • 8.3.1. MARKET ESTIMATES & SIZES
    • 8.3.2. KEY GROWTH ENABLERS
    • 8.3.3. KEY CHALLENGES
    • 8.3.4. KEY PLAYERS
    • 8.3.5. COUNTRY ANALYSIS
      • 8.3.5.1. CHINA
      • 8.3.5.2. JAPAN
      • 8.3.5.3. INDIA
      • 8.3.5.4. SOUTH KOREA
      • 8.3.5.5. INDONESIA
      • 8.3.5.6. SINGAPORE
      • 8.3.5.7. TAIWAN
      • 8.3.5.8. AUSTRALIA & NEW ZEALAND
      • 8.3.5.9. REST OF ASIA-PACIFIC
  • 8.4. REST OF WORLD
    • 8.4.1. MARKET ESTIMATES & SIZES
    • 8.4.2. KEY GROWTH ENABLERS
    • 8.4.3. KEY CHALLENGES
    • 8.4.4. KEY PLAYERS
    • 8.4.5. REGIONAL ANALYSIS
      • 8.4.5.1. LATIN AMERICA
      • 8.4.5.2. MIDDLE EAST & AFRICA

9. COMPETITIVE LANDSCAPE

  • 9.1. KEY STRATEGIC DEVELOPMENTS
    • 9.1.1. MERGERS & ACQUISITIONS
    • 9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    • 9.1.3. PARTNERSHIPS & AGREEMENTS
    • 9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
  • 9.2. COMPANY PROFILES
    • 9.2.1. BAYER AG
    • 9.2.2. BRACCO DIAGNOSTIC INC
    • 9.2.3. DAIICHI SANKYO COMPANY LIMITED
    • 9.2.4. GE HEALTHCARE
    • 9.2.5. KONINKLIJKE PHILIPS NV
    • 9.2.6. LANTHEUS MEDICAL IMAGING INC
    • 9.2.7. NANOPET PHARMA GMBH
    • 9.2.8. SANOCHEMIA PHARMAZEUTIKA GMBH
    • 9.2.9. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO LTD
    • 9.2.10. SIEMENS HEALTHINEERS AG
    • 9.2.11. TAEJOON PHARM
    • 9.2.12. TRIVITRON HEALTHCARE
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제